Fatsiphloginum exhibits anti-inflammatory [antiphlogogenic], analgetic [analgesic, antinociceptive] and antipyretic properties, reduces morbidity, hyperemia, swelling in the joints, which conditions increase in range of motions.
Fatsiphloginum exhibits anti-inflammatory [antiphlogogenic], analgetic [analgesic, antinociceptive] and antipyretic properties, reduces morbidity, hyperemia, swelling in the joints, which conditions increase in range of motions.
Instruction
Fatsiphloginum
CHEMICAL COMPOSITION: Active components of Fatsiphloginum are: triterpene glycosides-fatsiosides.
PHARMACOLOGICAL FEATURES: Fatsiphloginum exhibits anti-inflammatory [antiphlogogenic], analgetic [analgesic, antinociceptive] and antipyretic properties, reduces morbidity, hyperemia, swelling in the joints, which conditions increase in range of motions.
Analgetic and antipyretic action is revealed 1,5-2 hours after administration of the drug. As for reduction in occurrence of inflammation, namely, in the joints, after the first or the second week of treatment.
THERAPEUTIC INDICATIONS: rheumatoid joint inflammation, osteoarthritis, ankylosing [rheumatoid] spondylitis, rheumatism, osteoarthritis deformans, reactive synovitis, osteochondrosis, tendinitis, tendovaginitis, gout, pain in spine, myalgia, traumatic inflammation of soft tissues and support-motor [locomotor] apparatus.
DOSAGE AND DIRECTIONS FOR USE: one-time and daily dosage is established individually, in adults: 25-30 mg (0,0025-0,05g) Fatsiphloginum is swallowed three-four times daily, after meal, daily dosage up to 200 mg (0.2g).
SIDE EFFECTS AND SPECIAL PRECAUTIONS: unlike other nonsteroid anti-inflammatory medicaments (NSAID), Fatsiphloginum very rarely causes gastric irritation, expressed as moderate gastralgia, feelings of discomfort in the epigastric region, which is no reason for treatment cessation – reduction in dosage and observance of the diet, occurrence of gastric irritation vanishes.
In single cases Fatsiphloginum may cause increase in blood [arterial] pressure, nettle-rash type skin efflorescence, provided that such symptoms occur , Fatsiphloginum treatment should be ceased.
CONTRAINDICATION: Fatsiphloginum is contraindicated in patients with acute erosive- ulcer lesions of gastrointestinal tract, arterial hypertension, bronchial asthma (“aspirin asthma”), pregnancy during the last trimester, heart failure, renal insufficiency or hepatic insufficiency.
PRESENTATION: 50 mg tabletss – blisters # 60
STORAGE INSTRUCTIONS: Store in a cool and dry place. Protect from light.
SHELF LIFE: 4 years.